1. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon
- Author
-
Rebecca S Hesterberg, Matthew Beatty, Jessica M. McDaniel, Pearlie K. Epling-Burnette, Rainer Metcalf, Andreas Becker, Jeffrey A. Yoder, Ernst Schönbrunn, Rezaul M. Karim, Anjali M. Rajadhyaksha, Muhammad Ayaz, Kenyon G. Daniel, Aileen Y. Alontaga, Steven Gunawan, Yan Yang, Morgan E. Orobello, William E. Goodheart, Nicholas J. Lawrence, Afua A. Akuffo, Wayne C. Guida, and Harshani R. Lawrence
- Subjects
0301 basic medicine ,Proteasome Endopeptidase Complex ,T-Lymphocytes ,Ubiquitin-Protein Ligases ,Cell Cycle Proteins ,Protein degradation ,Ligands ,Biochemistry ,Conserved sequence ,Mice ,03 medical and health sciences ,Ubiquitin ,Cell Line, Tumor ,Animals ,Humans ,Immunologic Factors ,Nuclear protein ,Lenalidomide ,Molecular Biology ,Transcription factor ,Conserved Sequence ,Adaptor Proteins, Signal Transducing ,biology ,Chemistry ,Cereblon ,Nuclear Proteins ,Azepines ,Cell Biology ,Triazoles ,Cullin Proteins ,Thalidomide ,Ubiquitin ligase ,Cell biology ,030104 developmental biology ,Proteasome ,Molecular Probes ,Proteolysis ,Protein Structure and Folding ,biology.protein ,Peptide Hydrolases ,Transcription Factors - Abstract
Upon binding to thalidomide and other immunomodulatory drugs, the E3 ligase substrate receptor cereblon (CRBN) promotes proteosomal destruction by engaging the DDB1–CUL4A–Roc1–RBX1 E3 ubiquitin ligase in human cells but not in mouse cells, suggesting that sequence variations in CRBN may cause its inactivation. Therapeutically, CRBN engagers have the potential for broad applications in cancer and immune therapy by specifically reducing protein expression through targeted ubiquitin-mediated degradation. To examine the effects of defined sequence changes on CRBN's activity, we performed a comprehensive study using complementary theoretical, biophysical, and biological assays aimed at understanding CRBN's nonprimate sequence variations. With a series of recombinant thalidomide-binding domain (TBD) proteins, we show that CRBN sequence variants retain their drug-binding properties to both classical immunomodulatory drugs and dBET1, a chemical compound and targeting ligand designed to degrade bromodomain-containing 4 (BRD4) via a CRBN-dependent mechanism. We further show that dBET1 stimulates CRBN's E3 ubiquitin–conjugating function and degrades BRD4 in both mouse and human cells. This insight paves the way for studies of CRBN-dependent proteasome-targeting molecules in nonprimate models and provides a new understanding of CRBN's substrate-recruiting function.
- Published
- 2018
- Full Text
- View/download PDF